摘要
目的：评价注射用重组人IL-11（rhIL-11）衍生物及rhIL-11对恶性肿瘤化学治疗后血小板减少的疗效及安全性。方法收集恶性肿瘤化学治疗后出现Ⅲ～Ⅳ度血小板减少（≤50×10^9/L）患者63例，随机分为治疗组32例与对照组31例，于化学治疗结束后24～48 h开始，治疗组给予rhIL-11衍生物1.5 mg/d，对照组给予rhIL-113 mg/d，以血小板升至100×10^9/L为停药标准，比较两组血小板升至75×10^9/L 的时间及血小板升至100×10^9/L的时间，观察用药期间的不良反应发生情况。结果治疗组血小板升至75×10^9/L 的用药时间为（6.46±2.27）d，对照组血小板升至75×10^9/L的用药时间为（8.59±3.78）d，两组比较差异有统计学意义（P＜0.01）。治疗组血小板升至100×10^9/L的用药时间为（9.07±2.45）d；对照组血小板升至100×10^9/L的用药时间为（11.59±2.78）d，两组比较差异有统计学意义（P＜0.01）。两组不良反应发生率比较差异无统计学意义（P＞0.05）。结论 rhIL-11衍生物与rhIL-11对恶性肿瘤化学治疗后引起的血小板减少疗效确切。与rhIL-11相比，rhIL-11衍生物起效迅速，更有优势。
Objective To evaluate the efficacy and side effect of rhIL-11 derivatives and rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia in patients with malignant tumor. Methods A total of 63 malignant tumor patients with grade Ⅲ-Ⅳ thrombocytopenia （≤50 ×10^9/L）after chemotherapy were collected and divided into treatment group and control group. At 24-48 hours after chemotherapy,the patients in treatment group received rhIL-11 derivatives 1.5 mg per day,while the patients in control group receive-drhIL-11 3 mg per day. The treatment would be ended when the platelets rose up to 1 00 ×10^9/L. The treat-ment time taken to get platelet rise up to 75 ×10^9/L or 1 00×10^9/L was compared between two groups. Ad-verse effects were observed during the treatment. Results There was a significant difference in the treatment time used to raise platelet up to 75×10^9/L between the treatment group （6.46 ±2.27）days and the control group （6.46 ±2.27）days （P〈0.01 ）. There was also a significant difference in the treatment time used to raise platelet up to 1 00 ×10^9/L between the treatment group （9.07 ±2.45 ）days and the control group （11.59 ±2.78）days （P〈0.01 ）. The incidences of adverse effects between two groups showed no significant difference （P〉0.05 ）. Conclusion Bothe rhIL-11 derivatives and rhIL-11 are effective in the treatment of chemotherapy-induced thrombocytopenia in patients with malignant tumor. The rhIL-11 derivatives has a more rapid effect to exhibit a slight advantage over rhIL-11.
出处
《新医学》
2014年第5期297-299,共3页
Journal of New Medicine
基金
辽宁省科技厅科技攻关项目(2013225021)
